|
|
 |
Severe neutropenic events occur frequently in many tumor types
Findings from a large prospective community practice database on hematologic
parameters following chemotherapy (the Awareness of Neutropenia in Chemotherapy
[ANC] Registry) demonstrated that the rates of neutropenia and febrile neutropenia
vary with tumor type and treatment.1
|
|
|
|
Incidence of severe neutropenic events* (by tumor type)2
|
* ANC < 0.5 x 109/L or neutropenic complications such
as fever, infection, etc. |
|
|
|
|
The Awareness of Neutropenia in Chemotherapy (ANC) Registry is a large prospective
registry that is following more than 3,500 patients with a variety of major
tumor types (breast, lung, lymphoma, ovarian, and colorectal) initiating a new
chemotherapy regimen at 137 randomly selected clinical sites across the United
States. This nationwide study was undertaken to better define the risk of
neutropenia and its complications and to develop a risk model for febrile
neutropenia in cancer patients receiving chemotherapy.3,4 Primary neutropenic
outcomes include neutropenia (absolute neutrophil count [ANC] nadir < 1.0 x 109/L),
severe neutropenia (ANC nadir < 0.5 x 109/L), febrile neutropenia (fever or
infection and ANC nadir < 1.0 x 109/L), and severe febrile neutropenia (fever or
infection and ANC nadir < 0.5 x 109/L). Other primary outcomes include relative
dose intensity overall and by cycle of chemotherapy.5
|
|
|
|
Patients are at greatest risk of neutropenic events in the first cycle of chemotherapy |
|
The risk of neutropenic events is greatest in the first cycle of chemotherapy |
|
The risk for initial neutropenia is greater in the first cycle of chemotherapy than in the 3 subsequent cycles combined.3
|
|
|
|
50% or more of initial episodes of febrile neutropenia occur in cycle 1 across tumor types
The initial episode of febrile neutropenia is most likely to occur during the first cycle of chemotherapy across all major tumor types.5
Incidence of initial febrile neutropenia† (by select tumor type)5
|
†Fever or infection and ANC nadir < 1.0 x 109/L.
|
|
|
|
|
The majority of febrile neutropenia-related events occur during the first cycle of chemotherapy
Of those patients who developed febrile neutropenia, two thirds did so in the first cycle of moderately myelosuppressive* chemotherapy |
|
Incidence of febrile neutropenia events by cycle without growth factor support6
|
 |
 |
Phase 3, multicenter, randomized, double-blind, placebo-controlled trial studied patients with breast cancer (N = 928) randomly assigned to either placebo (n = 465) or Neulasta® (n = 463) on day 2 of each 21-day chemotherapy cycle of 100 mg/m2 docetaxel. Patients who experienced febrile neutropenia in the double-blind phase of the study were converted to open-label Neulasta® treatment for subsequent cycles of chemotherapy. |
|
|
|
|
*Regimens associated with ≥ 17% incidence of febrile neutropenia (temperature ≥ 38.2ºC and ANC < 0.5 x 109/L) in the absence of growth factor support. |
|
|
|
See Important Product Safety Information.
|
|
|
